An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. (2019)

First Author: Vuong L

Attributed to: MRC Centre for Regenerative Medicine funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/0008-5472.can-18-2244

PubMed Identifier: 30674531

Publication URI: http://europepmc.org/abstract/MED/30674531

Type: Journal Article/Review

Volume: 79

Parent Publication: Cancer research

Issue: 7

ISSN: 0008-5472